Clinical Trial Setback Sends Intellia Shares Plummeting
07.11.2025 - 06:13:04 | boerse-global.de
Intellia Therapeutics faced a severe market downturn following the disclosure of a patient death in a pivotal Phase 3 clinical trial. The biotechnology firm’s stock experienced a dramatic collapse, plummeting an additional 27% during after-hours trading after already closing the regular session with a 9% decline.
The devastating news emerged from the MAGNITUDE study evaluating the company’s lead candidate, nexiguran ziclumeran (nex-z). This CRISPR-based therapeutic targets transthyretin amyloidosis, a progressive and frequently fatal condition. On November 6, CEO John Leonard confirmed the passing of a participant who had previously developed severe liver complications. Leonard expressed that the company was “deeply affected to learn the patient with Grade 4 liver transaminase elevations passed away Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt kostenlos anmelden
Jetzt abonnieren.
